SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

EyePoint Pharmaceuticals, Inc. – ‘8-K’ for 1/23/20

On:  Thursday, 1/23/20, at 1:11pm ET   ·   For:  1/23/20   ·   Accession #:  1564590-20-1745   ·   File #:  0-51122

Previous ‘8-K’:  ‘8-K/A’ on 1/16/20 for 1/13/20   ·   Next:  ‘8-K’ on 2/4/20 for 2/3/20   ·   Latest:  ‘8-K’ on / for 3/7/24   ·   5 References:   

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 1/23/20  EyePoint Pharmaceuticals, Inc.    8-K:2,9     1/23/20    2:67K                                    ActiveDisclosure/FA

Current Report   —   Form 8-K   —   Sect. 13 / 15(d) – SEA’34
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 8-K         Current Report                                      HTML     21K 
 2: EX-99.1     Miscellaneous Exhibit                               HTML     19K 


‘8-K’   —   Current Report


This is an HTML Document rendered as filed.  [ Alternative Formats ]



 <!   C: 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of report (Date of earliest event reported): January 23, 2020

 

EyePoint Pharmaceuticals, Inc.

(Exact Name of Registrant as Specified in Charter)

 

 

Delaware

 

000-51122

 

26-2774444

(State or Other Jurisdiction

of Incorporation)

 

(Commission

File Number)

 

(I.R.S. Employer

Identification No.)

 

480 Pleasant Street

Watertown, MA 02472

(Address of Principal Executive Offices, and Zip Code)

(617) 926-5000

Registrant’s Telephone Number, Including Area Code

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of

each class

 

Trading

Symbol(s)

 

Name of each exchange

on which registered

Common Stock, par value $0.001

 

EYPT

 

The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company  

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  

 

 


 

Item 2.02. Results of Operations and Financial Condition.

On January 23, 2020, EyePoint Pharmaceuticals, Inc. (the “Company”) issued a press release announcing its preliminary fourth quarter and full-year 2019 revenues. A copy of the press release is filed as Exhibit 99.1 hereto.

 

The information included under Item 2.02 of this current report on Form 8-K, including Exhibit 99.1, is deemed filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and, therefore, may be incorporated by reference in filings under the Securities Act of 1933, as amended.

Item 9.01.    Financial Statements and Exhibits.

(d) Exhibits.

 

Exhibit No.

  

Description

 

 

99.1

  

Press release of EyePoint Pharmaceuticals, Inc., dated January 23, 2020.

 

 

 

 


 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

EyePoint Pharmaceuticals, Inc.

 

 

Date: January 23, 2020

 

By:

 

/s/ Nancy Lurker

 

 

Name:

 

Nancy Lurker

 

 

Title

 

President and Chief Executive Officer

 

 


Dates Referenced Herein   and   Documents Incorporated by Reference

This ‘8-K’ Filing    Date    Other Filings
Filed on / For Period end:1/23/20None on these Dates
 List all Filings 


5 Subsequent Filings that Reference this Filing

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 2/12/21  EyePoint Pharmaceuticals, Inc.    S-3                    3:260K                                   Donnelley … Solutions/FA
 2/02/21  EyePoint Pharmaceuticals, Inc.    424B5                  1:493K                                   Donnelley … Solutions/FA
 2/01/21  EyePoint Pharmaceuticals, Inc.    424B5                  1:496K                                   Donnelley … Solutions/FA
 1/15/21  EyePoint Pharmaceuticals, Inc.    S-3                    4:662K                                   Donnelley … Solutions/FA
11/06/20  EyePoint Pharmaceuticals, Inc.    S-8        11/06/20    3:88K                                    Donnelley … Solutions/FA
Top
Filing Submission 0001564590-20-001745   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Fri., Mar. 29, 12:03:17.1pm ET